Kestra Advisory Services’s Corcept Therapeutics CORT Stock Holding History

Kestra Advisory Services’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$941K	Sell	8,170 -2,744	-25%	-$295K	﹤0.01%	2009
2026 Q2	$949K	Buy	+10,914	New	+$659K	﹤0.01%	1868
2026 Q1	–	Sell	-5,194	Closed	-$181K	–	3364
2025 Q4	$181K	Sell	5,194 -1,653	-24%	-$130K	﹤0.01%	2982
2025 Q3	$569K	Sell	6,847 -346	-5%	-$25K	﹤0.01%	1964
2025 Q2	$528K	Buy	7,193 +286	+4%	+$20.7K	﹤0.01%	1931
2025 Q1	$789K	Sell	6,907 -2,618	-27%	-$159K	﹤0.01%	1537
2024 Q4	$480K	Buy	9,525 +1,039	+12%	+$54.4K	﹤0.01%	1899
2024 Q3	$393K	Sell	8,486 -15,860	-65%	-$564K	﹤0.01%	1920
2024 Q2	$791K	Sell	24,346 -6,488	-21%	-$178K	﹤0.01%	1474
2024 Q1	$777K	Buy	+30,834	New	+$728K	0.01%	1400
2021 Q1	–	Sell	-10,072	Closed	-$264K	–	1887
2020 Q4	$264K	Buy	+10,072	New	+$212K	﹤0.01%	1533

Other funds holding CORT

Parallel Advisors San Francisco, California $7.42B AUM 27.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Boston Trust Walden Boston, Massachusetts $12.4B AUM 21.62% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Granite Investment Partners El Segundo, California $1.84B AUM 35.93% 1-Year Est. Return

Kestra Advisory Services's CORT Position: Q3 2026 in Review

Kestra Advisory Services reduced its Corcept Therapeutics (CORT) stake by 25% in Q3 2026, selling an estimated $295K and leaving 8,170 shares worth $941K. The position accounts for ﹤0.01% of the portfolio, ranked #2009.

Kestra Advisory Services first reported a position in CORT in Q4 2020 and has held it in 11 quarters since. The position peaked at $949K in Q2 2026. 216 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

Kestra Advisory Services held 8,170 shares of Corcept Therapeutics worth $941K as of Q3 2026.
Kestra Advisory Services sold 2,744 Corcept Therapeutics shares in Q3 2026, an estimated $295K.
Corcept Therapeutics made up ﹤0.01% of Kestra Advisory Services's portfolio in Q3 2026, its #2009 holding.
Kestra Advisory Services first reported a position in Corcept Therapeutics in Q4 2020 and has held it in 11 quarters since.
Kestra Advisory Services's Corcept Therapeutics position peaked at $949K in Q2 2026.
216 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Kestra Advisory Services's 13F filing for Q3 2026, filed 2 Nov 2026.